Exemestane Export Market Intelligence: India's 87 Suppliers Shipping to 57 Countries — TransData Nexus 2026

Q: Who are the top exemestane exporters from India?

The top exemestane exporters from India are: 1. INTAS PHARMACEUTICALS LIMITED — $4.5M (31.1% market share); 2. EUGIA PHARMA SPECIALITIES LIMITED — $2.2M (15.4% market share); 3. SUN PHARMACEUTICAL INDUSTRIES LIMITED — $1.8M (12.3% market share); 4. MSN LABORATORIES PRIVATE LIMITED — $1.7M (12.0% market share); 5. CIPLA LIMITED — $1.1M (7.3% market share). Together they account for 78.1% of India's total exemestane export value.

Q: What is the total export value of exemestane from India?

The total export value of exemestane from India is $14.5M USD, recorded across 1,533 shipment transactions from 87 active exporters to 57 destination countries. The average shipment value is $9.4K.

Q: Which countries import exemestane from India?

India exports exemestane to 57 countries worldwide. The top importing countries are: UNITED STATES (39.3% share, $5.7M), BRAZIL (12.2% share, $1.8M), NETHERLANDS (11.7% share, $1.7M), UNITED KINGDOM (9.7% share, $1.4M), GERMANY (6.1% share, $882.2K). These five markets account for 78.9% of total export value.

Q: What is the HS code for exemestane exports from India?

The primary HS code for exemestane exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of exemestane exports from India?

The average unit price for exemestane exports from India is $47.52 USD per unit, with prices ranging from $0.01 to $6892.13 depending on formulation, packaging, and order volume. The total market is valued at $14.5M across 1,533 shipments.

Q: Which ports handle exemestane exports from India?

The primary ports for exemestane exports from India are SAHAR AIR CARGO ACC (INBOM4) (20.5% of shipments), DELHI AIR CARGO ACC (INDEL4) (17.8% of shipments), SAHAR AIR (16.7% of shipments), DELHI AIR (8.3% of shipments), Bombay Air Cargo (4.0% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of exemestane?

India is one of the world's leading exporters of exemestane due to its large base of 87 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports exemestane to 57 countries, demonstrating 29% global market coverage.

Q: What certifications do Indian exemestane exporters need?

Indian exemestane exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import exemestane from India?

There are 196 registered buyers importing exemestane from India, spread across 57 countries. The repeat buyer rate is 57.7%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top exemestane supplier from India?

INTAS PHARMACEUTICALS LIMITED is the leading exemestane exporter from India with a market share of 31.1% and total export value of $4.5M across 260 shipments. The top 5 suppliers together control 78.1% of total export value.

Suresh Sormare

Exemestane

India Pharmaceutical Trade Intelligence

$14.5M87 Suppliers57 CountriesHS 30049049

ExportsIndia → UNITED STATES39.3%India → BRAZIL12.2%

ImportsUNITED STATES → India$163.0K ITALY → India$146.4K

#1 Supplier: INTAS PHARMACEUTICALS #1 Buyer: CARDINAL HEALTH

Exemestane Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Exemestane to the World

Between 2022 and 2026, India exported $14.5M worth of exemestane across 1,533 verified shipments to 57 countries — covering 29% of world markets in the Advanced Oncology segment. The largest destination is UNITED STATES (39.3%). INTAS PHARMACEUTICALS LIMITED leads with a 31.1% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Exemestane export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Exemestane export data snapshot — $14.5M · 87 exporters · 57 countriesTransData Nexus · Indian Customs Data

Top Exemestane Exporters from India

87 active exporters · Ranked by export value

View all 87 →

Top Exemestane Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	INTAS PHARMACEUTICALS LIMITED	$4.5M	260	21	31.1%
2	EUGIA PHARMA SPECIALITIES LIMITED

Top Countries Importing Exemestane from India

57 destination markets · Ranked by import value

All 57 countries →

Top Countries Importing Exemestane from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$5.7M	39.3%
2	BRAZIL	$1.8M	12.2%
3	NETHERLANDS	$1.7M	11.7%
4	UNITED KINGDOM	$1.4M	9.7%
5	GERMANY	$882.2K	6.1%
6	MEXICO	$446.1K	3.1%
7	HUNGARY	$412.2K	2.8%
8	GREECE	$242.9K	1.7%
9	AUSTRALIA	$224.2K	1.5%
10	VENEZUELA	$215.1K	1.5%

UNITED STATES is India's largest exemestane export destination, absorbing 39.3% of total exports worth $5.7M. The top 5 importing countries — UNITED STATES, BRAZIL, NETHERLANDS, UNITED KINGDOM, GERMANY — together account for 78.9% of India's total exemestane export value. The remaining 52 destination countries collectively receive the other 21.1%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Exemestane to India?

4 origin countries · Total import value: $344.8K

India imports exemestane from 4 countries with a combined import value of $344.8K. The largest supplier is UNITED STATES ($163.0K, 4 shipments), followed by ITALY and SWITZERLAND. All values are from Indian Customs (DGFT) import records.

Countries Supplying Exemestane to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$163.0K	4	47.3%
2	ITALY	$146.4K	4	42.5%
3	SWITZERLAND	$33.5K	3	9.7%
4	POLAND	$1.8K	1	0.5%

UNITED STATES is the largest supplier of exemestane to India, accounting for 47.3% of total import value. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Exemestane

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, Exemestane is approved for medical use, with the brand name Aromasin receiving FDA approval on October 21, 1999. Subsequently, several generic versions have been approved:

- Breckenridge Pharmaceuticals on February 21, 2019
- Cipla Limited on April 27, 2018
- Eugia Pharma Specialities Limited on May 20, 2022
- Qilu Pharmaceutical on April 13, 2020
- Rising Pharmaceuticals on March 10, 2017
- Upsher-Smith Laboratories on July 26, 2017

These approvals indicate a competitive generic market for Exemestane in the U.S. Notably, EUGIA PHARMA SPECIALITIES LIMITED, a significant Indian exporter, received its ANDA approval in May 2022, aligning with its substantial export share. As of March 2026, there are no FDA import alerts or significant regulatory actions against Exemestane products from Indian manufacturers, suggesting compliance with U.S. regulatory standards.

2EU & UK Regulatory Framework

In the European Union, Exemestane is authorized for marketing under various brand names and generic formulations. The European Medicines Agency (EMA) ensures that these products meet stringent safety, efficacy, and quality standards. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of Exemestane products. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to these regions, ensuring that production processes meet high-quality standards.

3WHO Essential Medicines & Global Standards

Exemestane is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion underscores its importance in treating hormone-receptor-positive breast cancer globally. The WHO Model List serves as a guide for countries to develop their national essential medicines lists, promoting access to vital medications. Exemestane formulations are standardized across major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy.

4India Regulatory Classification

In India, Exemestane is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, Exemestane is not listed under the Drugs (Prices Control) Order (DPCO), and thus, its price is not subject to government-mandated ceilings. For exports, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national and international regulatory requirements.

5Patent & Exclusivity Status

The primary patent for Exemestane has expired, leading to the approval and market entry of multiple generic versions. This has intensified competition among manufacturers and exporters, contributing to the substantial export volumes from India. The absence of active patents facilitates broader access and affordability of Exemestane in global markets.

6Recent Industry Developments

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming the inclusion of Exemestane in the 24th edition published in September 2025. This highlights the ongoing global recognition of Exemestane's therapeutic value.

In February 2026, the FDA approved a generic version of Exemestane by Breckenridge Pharmaceuticals, further increasing the availability of this medication in the U.S. market. This approval reflects the FDA's commitment to enhancing access to essential medicines through the approval of generics.

These developments underscore the dynamic nature of the pharmaceutical industry and the critical role of regulatory bodies in ensuring the availability and affordability of essential medicines like Exemestane.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Exemestane

Retail & reference prices across 9 markets vs. India FOB export price of $47.52/unit

Global Price Benchmark for Exemestane across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$10.00	USD	According to the FDA's Orange Book, Exemestane is approved for use in the United States.
United Kingdom	$6.50	GBP	The UK's National Health Service (NHS) includes Exemestane in its Drug Tariff, indicating its availability and regulated pricing within the healthcare system.
Germany	$6.60	EUR	The European Medicines Agency (EMA) has approved Exemestane for use across EU member states, including Germany. (ema.europa.eu)
Australia	$5.60

Supply Chain Risk Assessment — Exemestane

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 60–70% of KSMs are imported from China, making the supply chain vulnerable to disruptions. In recent years, environmental regulations in China have led to the shutdown of several chemical manufacturing units, causing supply shortages and price volatility for Indian API manufacturers.

2Supplier Concentration & Single-Source Risk

The export market for Exemestane is highly concentrated, with the top five Indian exporters accounting for 78.1% of total exports. INTAS PHARMACEUTICALS LIMITED leads with a 31.1% share, followed by EUGIA PHARMA SPECIALITIES LIMITED (15.4%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (12.3%), MSN LABORATORIES PRIVATE LIMITED (12.0%), and CIPLA LIMITED (7.3%). This concentration poses a risk, as any disruption affecting these key players could significantly impact global supply. To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme to boost domestic API production and reduce dependency on imports. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules used in antibiotics, marking a step towards self-reliance.

Geopolitical & Shipping Disruptions

Access Complete Exemestane Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 1,533 transactions across 57 markets.

Request Demo View Pricing

Frequently Asked Questions — Exemestane Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top exemestane exporters from India?

The leading exemestane exporters from India are INTAS PHARMACEUTICALS LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, and 8 others. INTAS PHARMACEUTICALS LIMITED leads with 31.1% market share ($4.5M). The top 5 suppliers together control 78.1% of total export value.

What is the total export value of exemestane from India?

The total export value of exemestane from India is $14.5M, recorded across 1,533 shipments from 87 active exporters to 57 countries. The average shipment value is $9.4K.

Which countries import exemestane from India?

India exports exemestane to 57 countries. The top importing countries are UNITED STATES (39.3%), BRAZIL (12.2%), NETHERLANDS (11.7%), UNITED KINGDOM (9.7%), GERMANY (6.1%), which together account for 78.9% of total export value.

What is the HS code for exemestane exports from India?

The primary HS code for exemestane exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Exemestane

Exemestane

Top Exemestane Exporters from India

Top Countries Importing Exemestane from India

Who Supplies Exemestane to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Exemestane

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Exemestane

Supply Chain Risk Assessment — Exemestane

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Geopolitical & Shipping Disruptions

Access Complete Exemestane Trade Intelligence

Frequently Asked Questions — Exemestane Exports from India

Who are the top exemestane exporters from India?

What is the total export value of exemestane from India?

Which countries import exemestane from India?

What is the HS code for exemestane exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

4Risk Mitigation Recommendations

What is the average price of exemestane exports from India?

Which ports handle exemestane exports from India?

Why is India a leading exporter of exemestane?

What certifications do Indian exemestane exporters need?

How many buyers import exemestane from India?

What is the market share of the top exemestane exporter from India?

Analysis Methodology